Polycystic Ovaries and Effects of Hormones: An Observational Study in Females of Southern Assam
Authors/Creators
- 1. M. Sc. Biotechnology, Chandigarh University, Punjab
- 2. Associate Professor, Radiology, Diphu Medical College and Hospital, Diphu, Assam
- 3. Research Associate (Biotechnology/Life Science), Dr. Bholanath Chakraborty Memorial Fundamental Research Laboratory of Homoeopathy
- 4. Medical Director, Jeevan Jyoti Institute of Medical Sciences, Silchar, Assam
- 5. Assistant Professor, Gurucharan College, Silchar, Assam
- 6. Research Scholar, Department of Biotechnology, Assam University, Assam
- 7. Assistant Professor, Department of Pathology, Silchar Medical College and Hospital, Silchar, Assam
Description
Introduction and Objective: Polycystic Ovarian Syndrome also called as PCOS or PCOD (Polycystic Ovarian Disorder) This disorder is an endocrinopathy, and that’s why it should be referred to as PCOS, a syndrome rather than a disease. Amenorrhoea, weight gain, hirsutism, diabetes mellitus, hypertension, cardiovascular disease, cerebrovascular disease, breastmilk expression in absence of pregnancy and infertility are some of the clinical manifestations caused by PCOS. The objective of this study was to observe the various hormonal and biochemical factors that influence PCOS in the Barak valley region of Assam. Methodology: A total number of 20 cases of reproductive age group of 18-38 yrs were selected for the study fulfilling the following criteria’s: USG > 12 antral follicles and clinical complaints and findings with anovulation and hyperandrogenism Glucose estimation was done by GOD POD (glucose oxidase peroxidase). The tests were carried out in semiautomated biochemistry analyser (ERBA Transasia) HBA1c estimation was done by Turbodyne SC Tulip and hormonal analysis was done by Classic radiance semiautomated CLIA plate analyser. Free testosterone was done from outsource. Results: 7 cases are hypogonadotrophic and 13 cases are normogonadotrophic subjects who presented with polycystic ovaries. High TSH was found in 15.4% high LH/FSH ratio in 61.5% high prolactin in 69.2%, low prolactin in 15.4% high AMH in 84.6% and high insulin in 30.8% of cases The status of ANOVA shows a significant p value of <0.05 for LH and insulin. High AMH and high LH/FSH ratio were responsible for PCOS. Conclusion: Hormonal abnormalities hamper the normal folliculogenesis, hence needs corelation and correction.
Abstract (English)
Introduction and Objective: Polycystic Ovarian Syndrome also called as PCOS or PCOD (Polycystic Ovarian Disorder) This disorder is an endocrinopathy, and that’s why it should be referred to as PCOS, a syndrome rather than a disease. Amenorrhoea, weight gain, hirsutism, diabetes mellitus, hypertension, cardiovascular disease, cerebrovascular disease, breastmilk expression in absence of pregnancy and infertility are some of the clinical manifestations caused by PCOS. The objective of this study was to observe the various hormonal and biochemical factors that influence PCOS in the Barak valley region of Assam. Methodology: A total number of 20 cases of reproductive age group of 18-38 yrs were selected for the study fulfilling the following criteria’s: USG > 12 antral follicles and clinical complaints and findings with anovulation and hyperandrogenism Glucose estimation was done by GOD POD (glucose oxidase peroxidase). The tests were carried out in semiautomated biochemistry analyser (ERBA Transasia) HBA1c estimation was done by Turbodyne SC Tulip and hormonal analysis was done by Classic radiance semiautomated CLIA plate analyser. Free testosterone was done from outsource. Results: 7 cases are hypogonadotrophic and 13 cases are normogonadotrophic subjects who presented with polycystic ovaries. High TSH was found in 15.4% high LH/FSH ratio in 61.5% high prolactin in 69.2%, low prolactin in 15.4% high AMH in 84.6% and high insulin in 30.8% of cases The status of ANOVA shows a significant p value of <0.05 for LH and insulin. High AMH and high LH/FSH ratio were responsible for PCOS. Conclusion: Hormonal abnormalities hamper the normal folliculogenesis, hence needs corelation and correction.
Files
IJPCR,Vol16,Issue3,Article164.pdf
Files
(799.5 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:4f65f2c40ab1060cfd3e04a9283e2138
|
799.5 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-02-26
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue3,Article164.pdf
- Development Status
- Active
References
- 1. Sawant, Akshata, Sonali Patil, and Shruti Shah. "Review on PCOD/PCOS & its treatment in different medicinal systems–allopathy, ayurveda, homeopathy." Sci Jurno. 2017; 1:1: 1-16. 2. Carmina, Enrico, and Rogerio A. Lobo. "Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women." The journal of clinical endocrinology & metabolism. 1999; 84:6: 1897-1899. 3. Broekmans, F. J., et al. "PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO‐II anovulation and association with metabolic factors." BJOG: An International Journal of Obstetrics & Gynaecology. 2006; 113:10: 1210-1217. 4. Goldzieher, Joseph W., and James A. Green. "The polycystic ovary. I. Clinical and histologic features." The Journal of Clinical Endocrinology & Metabolism. 1962; 22:3: 325-338. 5. Dumitrescu, R., et al. "The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms." Journal of medicine and life. 2015; 8:2: 142. 6. Hall, Janet E., et al. "Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free α-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists." The Journal of Clinical Endocrinology & Metabolism. 1990; 70:2: 328-335. 7. Mcnatty, Kenneth P., et al. "The production of progesterone, androgens, and estrogens by granulosa cells, thecal tissue, and stromal tissue from human ovaries in vitro." The Journal of Clinical Endocrinology & Metabolism. 1979; 49:5: 687-699. 8. Lobo, Rogerio A. "Hirsutism in polycystic ovary syndrome: current concepts." Clinical obstetrics and gynecology. 1991; 34:4: 817- 826. 9. Deslypere, J. P., L. Verdonck, and A. Vermeulen. "Fat tissue: a steroid reservoir and site of steroid metabolism." The Journal of Clinical Endocrinology & Metabolism 61.3 (1985): 564-570. 10. De Leo, V., et al. "Genetic, hormonal and metabolic aspects of PCOS: an update." Reproductive Biology and Endocrinology. 2016; 14:1: 38. 11. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Practice & Research Clinical Obstetrics & Gynaecology. 2004 Oct 1; 18(5):671-83. 12. Hart R, Doherty DA, Norman RJ, Franks S, Dickinson JE, Hickey M, Sloboda DM. Serumantimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertility and sterility. 2010 Aug 1; 94(3):1118-21. 13. Dos Santos E, Dieudonné MN, Leneveu MC, Pecquery R, Serazin V, Giudicelli Y. In vitro effects of chorionic gonadotropin hormone on human adipose development. Journal of endocrinology. 2007 Aug 1; 194(2):313-26. 14. Escobar-Morreale, Héctor F., Manuel LuqueRamírez, and José L. San Millán. "The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome." Endocrine reviews. 2005; 26(2): 251-282. 15. Qiao, Jie, and Huai L. Feng. "Extra-and intraovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence." Human reproduction update. 2011; 17(1): 17-33. 16. Visser, Jenny A., et al. "Anti-Mullerian hormone: a new marker for ovarian function." Reproduction. 2006; 131(1): 1-9. 17. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. The Journal of Clinical Endocrinology & Metabolism. 2004 Jan 1; 89(1):318-23. 18. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, Dewailly D. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. The Journal of Clinical Endocrinology & Metabolism. 2003 Dec 1; 88(12):5957-62. 19. Chiu, Ken C., et al. "Hypovitaminosis D is associated with insulin resistance and β cell dysfunction." The American journal of clinical nutrition. 2004; 79(5): 820-825. 20. Clin Endocrinol Metab.1962; 22:325. 21. Thomson, Rebecca L., Simon Spedding, and Jonathan D. Buckley. "Vitamin D in the aetiology and management of polycystic ovary syndrome." Clinical endocrinology. 2012; 77(3): 343-350. 22. Yildizhan, Recep, et al. "Serum 25- hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome." Archives of gynecology and obstetrics. 2009; 280(4): 559. 23. Giudice, Linda C. "Endometrium in PCOS: implantation and predisposition to endocrine CA." Best practice & research Clinical endocrinology & metabolism 2006;20:2: 235-244. 24. Rotterdam ESHRE/ASRM‐Sponsored PCOS Consensus Workshop Group. "Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS)." Human reproduction 2004; 19:1: 41-47. 25. Carmina, E., et al. "Endothelial dysfunction in PCOS: role of obesity and adipose hormones." The American journal of medicine 2006; 119:4: 356-e1. 26. Schmidt, Johanna, et al. "Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled followup study." The Journal of Clinical Endocrinology & Metabolism. 2011; 96:12: 3794-3803. 27. Dumesic, Daniel A., and Rogerio A. Lobo. "Cancer risk and PCOS." Steroids. 2013; 78:8: 782-785.